• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Immunocore Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/7/25 7:33:58 AM ET
    $IMCR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMCR alert in real time by email
    false000167192700-000000000016719272025-05-072025-05-070001671927imcr:OrdinaryShareNominalValueGBP0002PerShareMember2025-05-072025-05-070001671927us-gaap:CommonStockMember2025-05-072025-05-07

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549



    FORM 8-K


    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 7, 2025



    Immunocore Holdings plc
    (Exact name of registrant as specified in its Charter)



    England and Wales
    001-39992
    Not Applicable
    (State or other jurisdiction of incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)

    92 Park Drive, Milton Park, Abingdon,
    Oxfordshire,
    United Kingdom
     
    OX14 4RY
    (Address of principal executive offices)
     
    (Zip Code)
    +44 1235 438600
    (Registrant’s telephone number, including area code)

    Not Applicable
    (Former name or former address, if changed since last report)



    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
    Trading
    Symbol(s)
    Name of each exchange on which registered
    American Depositary Shares, each representing one ordinary share, nominal value £0.002 per share
    IMCR
    NASDAQ
    Ordinary share, nominal value £0.002 per share*
    *
    NASDAQ

    * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02.
    Results of Operations and Financial Condition.

    On May 7, 2025, Immunocore Holdings plc (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025, as well as other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference.

    The information in this Item 2.02 of this Current Report on 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

    Item 9.01.
    Financial Statements and Exhibits

    Exhibit No.
    Description
    99.1
    Press Release dated May 7, 2025.
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    IMMUNOCORE HOLDINGS PLC
         
    Dated: May 7, 2025
    By:
    /s/ Bahija Jallal, Ph.D.
     
       
    Name:
    Bahija Jallal, Ph.D.
     
       
    Title:
    Chief Executive Officer
     



    Get the next $IMCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMCR

    DatePrice TargetRatingAnalyst
    5/27/2025$65.00Buy
    Deutsche Bank
    12/13/2024$74.00 → $35.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2024$72.00 → $38.00Outperform → Neutral
    Mizuho
    10/24/2024$24.00Sell
    UBS
    10/7/2024Buy → Neutral
    Guggenheim
    4/29/2024$74.00Outperform
    Leerink Partners
    11/20/2023$60.00Overweight
    JP Morgan
    11/2/2023Overweight
    Cantor Fitzgerald
    More analyst ratings